176 related articles for article (PubMed ID: 2424367)
1. Effects of 2,2'-O-cyclocytidine and acyclovir on latent herpes simplex virus in trigeminal ganglia of mice.
Liu WG; Chen ZJ; Song JZ; Ma ZX
Antimicrob Agents Chemother; 1986 Feb; 29(2):278-80. PubMed ID: 2424367
[TBL] [Abstract][Full Text] [Related]
2. [The effects of 2, 2'-O-cyclocytidine (CC) and acyclovir (ACV) on latent herpes simplex virus in trigeminal ganglia of mice].
Liu WG; Ma ZX; Chen ZJ; Song JZ
Yao Xue Xue Bao; 1985 Oct; 20(10):732-6. PubMed ID: 2424263
[No Abstract] [Full Text] [Related]
3. Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice.
Klein RJ; DeStefano E; Friedman-Kien AE; Brady E
Antimicrob Agents Chemother; 1981 May; 19(5):937-9. PubMed ID: 6271054
[TBL] [Abstract][Full Text] [Related]
4. Persistent reactivable latent herpes simplex virus infection in trigeminal ganglia of mice treated with antiviral drugs.
Svennerholm B; Vahlne A; Lycke E
Arch Virol; 1981; 69(1):43-8. PubMed ID: 6271097
[TBL] [Abstract][Full Text] [Related]
5. Effects of prolonged cultivation in the presence of acyclovir on recovery of latent herpes simplex virus from human trigeminal ganglia.
Lewis ME; Warren KG; Jeffrey VM; Tyrrell DL
Antimicrob Agents Chemother; 1983 Mar; 23(3):487-9. PubMed ID: 6303216
[TBL] [Abstract][Full Text] [Related]
6. [Combined therapy of acyclovir and cyclocytidine against herpes simplex virus].
Chen ZJ; Liu WG; Song JZ; Zhang Y
Zhongguo Yao Li Xue Bao; 1988 Jul; 9(4):364-6. PubMed ID: 2461639
[No Abstract] [Full Text] [Related]
7. Novobiocin and coumermycin A1 inhibit viral replication and the reactivation of herpes simplex virus type 1 from the trigeminal ganglia of latently infected mice.
Spivack JG; O'Boyle DR; Fraser NW
J Virol; 1987 Oct; 61(10):3288-91. PubMed ID: 3041048
[TBL] [Abstract][Full Text] [Related]
8. Effect of combined acyclovir and vidarabine on infection with herpes simplex virus in vitro and in vivo.
Park NH; Callahan JG; Pavan-Langston D
J Infect Dis; 1984 May; 149(5):757-62. PubMed ID: 6327850
[TBL] [Abstract][Full Text] [Related]
9. Effect of acyclovir, bromovinyldeoxyuridine, vidarabine, and L-lysine on latent ganglionic herpes simplex virus in vitro.
Park NH; Pavan-Langston D; Declercq E
Am J Med; 1982 Jul; 73(1A):151-4. PubMed ID: 6285706
[TBL] [Abstract][Full Text] [Related]
10. Characterization of latent infections in mice inoculated with herpes simplex virus which is clinically resistant to acyclovir.
Field HJ; Lay E
Antiviral Res; 1984 Apr; 4(1-2):43-52. PubMed ID: 6331304
[TBL] [Abstract][Full Text] [Related]
11. Expression of herpes simplex virus type 1 latency-associated transcripts in the trigeminal ganglia of mice during acute infection and reactivation of latent infection.
Spivack JG; Fraser NW
J Virol; 1988 May; 62(5):1479-85. PubMed ID: 2833602
[TBL] [Abstract][Full Text] [Related]
12. Ganglionic permissivity to HSV-1 replication and acyclovir-induced latency: an in vitro model.
Millin JA; Opremcak EM; Wells PA; Foster CS
Invest Ophthalmol Vis Sci; 1988 Feb; 29(2):232-8. PubMed ID: 2828264
[TBL] [Abstract][Full Text] [Related]
13. In vitro effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, 5'-amino-5-iodo-2',5'-dideoxyuridine and 2-deoxy-D-glucose on latent ganglionic herpes simplex virus infection.
Pavan-Langston D; Park NH; De Clercq E
Antiviral Res; 1984 Apr; 4(1-2):53-61. PubMed ID: 6331305
[TBL] [Abstract][Full Text] [Related]
14. Beta interferon plus gamma interferon efficiently reduces acyclovir-resistant herpes simplex virus infection in mice in a T-cell-independent manner.
Huang WY; Su YH; Yao HW; Ling P; Tung YY; Chen SH; Wang X; Chen SH
J Gen Virol; 2010 Mar; 91(Pt 3):591-8. PubMed ID: 19906941
[TBL] [Abstract][Full Text] [Related]
15. Experimental skin infection with an acyclovir resistant herpes simplex virus mutant: response to antiviral treatment and protection against reinfection.
Klein RJ; DeStefano E; Brady E; Friedman-Kien AE
Arch Virol; 1980; 65(3-4):237-46. PubMed ID: 6251784
[TBL] [Abstract][Full Text] [Related]
16. Effect of discontinuous acyclovir treatment on in vitro reactivation of herpes simplex virus from latently infected trigeminal ganglia.
Klein RJ; Friedman-Kien AE; DeStefano E
Antimicrob Agents Chemother; 1983 Jul; 24(1):129-31. PubMed ID: 6312871
[TBL] [Abstract][Full Text] [Related]
17. A herpes simplex virus type 1 mutant containing a nontransinducing Vmw65 protein establishes latent infection in vivo in the absence of viral replication and reactivates efficiently from explanted trigeminal ganglia.
Steiner I; Spivack JG; Deshmane SL; Ace CI; Preston CM; Fraser NW
J Virol; 1990 Apr; 64(4):1630-8. PubMed ID: 2157048
[TBL] [Abstract][Full Text] [Related]
18. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.
Coen DM; Kosz-Vnenchak M; Jacobson JG; Leib DA; Bogard CL; Schaffer PA; Tyler KL; Knipe DM
Proc Natl Acad Sci U S A; 1989 Jun; 86(12):4736-40. PubMed ID: 2543985
[TBL] [Abstract][Full Text] [Related]
19. Detection of herpes simplex virus type 1 transcripts during latent infection in mice.
Spivack JG; Fraser NW
J Virol; 1987 Dec; 61(12):3841-7. PubMed ID: 2824818
[TBL] [Abstract][Full Text] [Related]
20. Novel animal model for evaluating topical efficacy of antiviral agents: flux versus efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice.
Lee PH; Su MH; Kern ER; Higuchi WI
Pharm Res; 1992 Aug; 9(8):979-89. PubMed ID: 1329068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
